Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

NCT00864968 | Completed Phase 1

• 1 other identifier: AAI-US-493
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the relative bioavailability of nabumetone from 2 tablet products and determine if the 2 products were bioequivalent to each other.

Conditions

Healthy

Keywords

Bioequivalence; Nabumetone; Healthy subjects

Outcome Measures

Primary Outcomes (1)

• Rate and Extend of Absorption

  120 hours

Study Arms (2)

A

EXPERIMENTAL

Nabumetone 750 mg tablets, single dose

Drug: Nabumetone 750 mg tablets, single dose

B

ACTIVE COMPARATOR

Nabumetone 750 mg tablets, single dose

Drug: Nabumetone 750 mg tablets, single dose

Interventions

Nabumetone 750 mg tablets, single dose DRUG

A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions

Also known as: Nabumetone

A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy subjects at least 18 years of age.
• Availability of the subject for the entire study period and willingness to provide written informed consent after being informed of the nature of the study.
• Body mass index (BMI) between 18 and 30 kg/m2 (calculated using the BMI Calculator on the Centers for Disease Control and Prevention \[CDC\] website available at http://www.cdc.gov/nccdphp/dnpa/bmi/index.htm, last accessed 19 Mar 07) and a weight of at least 110 pounds.
• Good health as determined by a lack of clinically significant abnormalities in health assessments performed at Screening, as judged by the physician.
• Females were required to use a medically acceptable method of hormonal contraception or abstinence throughout the entire study period and for one week after the study is completed

You may not qualify if:

• Hypersensitivity to nabumetone (Nabumetone) or related compounds.
• Conditions that affected the absorption, metabolism, or passage of drugs out of the body (eg, sprue, celiac disease, Crohn's disease, colitis, liver, kidney, or thyroid conditions).
• Recent history (within 1 year) of mental illness, drug addiction, drug abuse, or alcoholism.
• A hematocrit value of ≤ 33.0% for females and ≤ 37.0% for males.
• Donation of \> 500 mL of blood in the past 8 weeks prior to study drug dosing or difficulty in donating blood.
• Receipt of an investigational drug within the 4 weeks prior to study drug dosing.
• Currently taking any systemic prescription medications, excluding hormone contraceptives, within the 7 days prior to study dosing or over-the-counter medication within 3 days of study dosing. This prohibition did not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications, as judged by the attending physician.
• Any nonprescription medication consumption reported was to be reviewed by the investigator prior to dosing. At the discretion of the investigator, these volunteers could be enrolled if the medication was not anticipated to alter study integrity.
• Regular smoking of more than 5 cigarettes weekly or the regular daily use of nicotinecontaining products beginning 3 months before study drug administration through the final evaluation.
• Female subjects who were lactating or had a positive pregnancy test at Screening and prior to each of the treatment periods.
• Alcohol, grapefruit beverages or foods, caffeine, or xanthine beverages or foods beginning 48 hours before each study drug administration through the last pharmacokinetic (PK) sample of each treatment period. Such restricted items included coffee, tea, iced tea, Coke®, Pepsi®, Mountain Dew®, chocolate, brownies, etc.
• Regular use of any drugs known to induce or inhibit hepatic drug metabolism (examples include barbiturates, carbamazepine, rifampin, phenylhydantoins, phenothiazines, cimetidine, omeprazole, macrolides, imidazoles, fluoroquinolones) within 30 days prior to study drug administration.
• Positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and hepatitis C antibody at Screening.
• No subject was allowed to enroll in this study more than once.

Sponsors & Collaborators

• Actavis Inc.: lead

Study Sites (1)

AAIPharma Inc., AAI Clinic

Morrisville, North Carolina, 27560, United States

Location

MeSH Terms

Interventions

Nabumetone

Intervention Hierarchy (Ancestors)

Butanones; Ketones; Organic Chemicals

Study Officials

• Evin H. Sides III, M.D.

  AAIPharma Inc., AAI Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: March 18, 2009
• First Posted: March 19, 2009
• Study Start: February 1, 2007
• Primary Completion: March 1, 2007
• Study Completion: March 1, 2007
• Last Updated: August 17, 2010

Record last verified: 2010-08

Locations

US (1)